Introduction
Retinitis pigmentosa (RP) is a group of inherited retinal degenerative diseases characterized by a progressive degeneration of rod and cone photoreceptor cells (PCs). RP is a major cause of blindness in adults, affecting approximately one in 3,500. 1, 2 This group of diseases is caused by mutations in various genes, including rhodopsin, cGMP phosphodiesterase b-subunit (PDE-b), and rds/peripherin. [3] [4] [5] Although extensive efforts have been made throughout the world to treat or cure RP, these diseases remain intractable.
Recently, advent gene therapy technology has been introduced as a possible novel therapeutic strategy for treating RP. Gene transfer vectors including recombinant adenovirus, adeno-associated virus (rAAV), and human immunodeficient virus (HIV)-based lentivirus have been employed and have shown significant therapeutic effects in animal models of RP. [6] [7] [8] [9] [10] [11] In the clinical setting, rAAV and lentivirus are likely to be better for RP than adenovirus, because both gene transfer to nondividing cells and long-lasting therapeutic effects are required to treat RP. [12] [13] [14] Several experimental approaches have been suggested by these studies, including (1) supplementation of a normal gene to PCs directly, 6, 9, 10, [15] [16] [17] (2) prevention of the accumulation of abnormal proteins by enhanced degradation using ribozyme in PCs, 8, 18 (3) inhibition of apoptotic loss of PCs via cellular antiapoptotic genes, 19 and (4) suppression of apoptotic loss of PCs via overexpression of neurotrophic factors. 7, 11, 20 Clearly, the tropism of each vector is a critical piece of information, because the former three strategies require highly efficient gene transfer to PCs.
We recently developed a novel lentiviral vector based on the simian immunodeficiency virus (SIV) from African green monkeys 21 and showed safe, stable, and long-term transgene expression over 1 year in the retinal tissue of adult rats under suitable titer. 22 According to our findings via repeated experiments, transgene expression using SIV was limited to the retinal pigment epithelium (RPE) via subretinal injection in young adult rats with the exception of accidental gene transfer to PCs. 22 This tropism of SIV suggests that gene transfer of the neurotrophic factor may be a better choice for treating RP.
Pigment epithelium-derived factor (PEDF) is a 50-kDa secreted glycoprotein, and was first isolated from conditioned medium from both fetal and adult RPE. 23, 24 PEDF binds to the glycosaminoglycans of the interphotoreceptor matrix, placing it in a prime physical location to affect the underlying neural retina. 25, 26 PEDF functions as a survival factor for cultured cerebellar granule cells, [27] [28] [29] spinal motor neurons, 30, 31 and hippocampal neurons 32 in vitro and delays the death of photoreceptor cells in the rd mouse in vivo. 33 In addition to its neurotrophic action, PEDF is antiangiogenic, inducing endothelial apoptosis via the Fas-Fas ligand system. [34] [35] [36] Our current study attempted to determine whether SIV-mediated PEDF gene transfer to the retina might correct the histological and functional deficits of PCs in a well-accepted animal model of RP, Royal College of Surgeons (RCS) rats, in which these deficits are caused by a mutation of the receptor tyrosine kinase Mertk, 37 which corresponds to the same kinase in human populations. 38 
Results

Histological assessment of transgene expression
We previously determined that SIV-mediated gene transfer was frequently seen in the RPE lasting more than 1 year stably, but was also occasionally detected in the PCs via the subretinal injection technique. 22 To examine whether these findings were also representative in RCS rats, we repeated nls-lacZ and human PEDF gene transfer. Transgene expressions were assessed by X-gal histochemistry for lacZ and by immunohistochemistry for PEDF at various time points (4, 8, 12 , and 24 weeks).
At 4 weeks after subretinal injection of SIV-nls-lacZ, frequent and widespread X-gal-positive blue spots were detected in the retina, almost coinciding with the area of vector injection, and especially in the RPE (Figures 1c and d) . These positive reactions were observed up to at least 24 weeks after gene transfer (Figure 1e ).
Immunohistochemical analysis showed that PEDF expression was observed in RPE only in the SIV-PEDFtreated retinas 4 weeks after injection (Figure 1f) , and the positive reaction was also found at all time points after gene transfer (4, 8, 12 , and 24 weeks after injection; data not shown). No positive reaction was observed in the retinas, either in the temporal hemisphere (Figure 1g ) or in the retinas treated with SIV-nls-lacZ (Figure 1h) , suggesting that the antibody used may not crossreact with rat PEDF.
Histological evaluation of photoreceptor cell degeneration
At various time points after the gene transfer (4, 8, 12 , and 24 weeks), the number of nuclei of PCs in each retinal area was counted to determine the effect of PEDF gene transfer on PC degeneration. At 4 weeks after injection, the retinas treated with PEDF demonstrated significant rescue of PCs in the nasal hemisphere (Po0.01), compared to the retinas that were not treated and to those treated with BSS or SIV-nls-lacZ (Figures 2a-e) . As shown in Figure 3a , the region nearest the injection site showed the greatest prevention of PC death, and in the three regions nearest to the injection site, PCs were significantly preserved by PEDF gene transfer, compared to the levels in controls. Similar and significant PC protections were also obtained at 8 and 12 weeks after injection. (Figures 3b-d) . Throughout the study period, neither severe inflammatory infiltration nor morphological change of RPE was seen in any of the retinas.
Evaluation of PC apoptosis by TUNEL staining
To confirm the frequency of PC apoptosis, we administered terminal dUTP-nicked end labeling (TUNEL) stain to the retinas 4 weeks after injection. The retinas of BSS and SIV-lacZ-injected eyes demonstrated scattered positive reactions against apoptosis in the thinned outer nuclear layer, as well as in the untreated control eyes (Figures 4a-c) . On the other hand, the number of apoptotic nuclei was significantly smaller in the retinas treated with SIV-PEDF (Figures 4a-c) . The density of TUNEL-positive photoreceptor nuclei was lower in the SIV-PEDF-treated retina than in the other control eyes (Figure 4d ).
Evaluation of retinal electrical function using electroretinograms
Dark-adapted electroretimograms (ERGs) were recorded at 4 and 8 weeks after subretinal injection to determine whether the histopathological protective effect of PEDF gene transfer on retinal degeneration might reflect retinal functions. A blinded examiner performed the ERG recording. At 4 weeks after the injection, the ERG responses had disappeared to a significant extent in the groups of untreated, balanced salt solution (BSS)-treated, and SIV-nls-lacZ-treated RCS rats, while significant amplitudes of a-and b-waves were observed in the group of SIV-PEDF-injected rats. In two of the six rats treated with lacZ, small but significant electrical responses were detected. Although the amplitudes gradually decreased in a time-dependent manner, a decline of the mean amplitudes of the a-and b-waves was significantly prevented by PEDF at 4 and 8 weeks after the gene transfer (Table 1) .
Discussion
In the present study, we clearly demonstrated that gene transfer of human PEDF, a neurotrophic factor, into RPE via our novel lentiviral vector SIV significantly delayed photoreceptor degeneration and electrophysiological defects in RCS rats. These findings suggest that there exists a neuroprotective effect of PEDF gene transfer in photoreceptor degenerative diseases.
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Possible gene therapy approaches to prevent retinal degeneration have been suggested, including (1) supplementation of normal gene to PCs directly, 6,9,10,15-17 (2) prevention of the accumulation of abnormal proteins by enhanced degradation using ribozyme in PCs, 8, 18 (3) inhibition of apoptotic loss of PCs via cellular antiapoptotic genes, 19 and (4) suppression of apoptotic loss of PCs via the overexpression of secreting neurotrophic factors, including FGF-2 20, 39 and CNTF. 7, 11, 40, 41 Clearly, the former three approaches require highly efficient gene transfer to PCs, while the latter does not, indicating that the tropism of the vector and the choice of promoter may be critical factors in the therapeutic outcome. We therefore first characterized the gene transfer of SIV with CMV promoter in the retina of RCS rats using nls-lacZ and PEDF genes.
As shown in Figure 1 , SIV-mediated retinal gene transfer driven by CMV promoter was relatively limited to the RPE, although it was rarely seen in some PCs. This result was equivalent to that reported previously in Wistar rats. 22 This gene transfer and expression profile suggests that, in the use of the SIV-CMV promoter construct, gene transfer of a secreting neurotrophic factor might be a reasonable approach. This approach may be advantageous compared to gene supplement approaches, because normal gene supplementation requires a number of different therapeutic genes and vectors for individuals. The use of neurotrophic factor may not always depend on the genetic status, which suggests a practical advantage in clinical settings.
PC protection gene therapy using neurotrophic factors has been evaluated and reported by some laboratories, 7, 11, 41 and these reports demonstrated a significant level of prevention of PC degeneration in RP model animals. Some of these studies, however, assessed the effects only at specific time points. Here, we examined (Table 1) , even though we confirmed immunohistochemically sustained expression of PEDF throughout the experimental course in vivo (data not shown). This limited biological effect of PEDF demonstrated in this study may be explained by (1) our limitation of the gene-transfer area to approximately 1/4-1/6 of the whole retinal square, or (2) the limited therapeutic potential of PEDF for retinal degeneration. The former limitation was an intentional part of our experimental design; we injected vectors to a limited area in order to obtain evidence of a therapeutic effect of PEDF that was specific to the transfer area, as well as to gain an internal control in the noninjected area of the same eye. Also, extensive detachment during gene transfer may cause traumatic loss of vision, which of course was not ethically acceptable. We are currently assessing the use of multiple small injections over a wider retinal region to determine whether extension of the gene-transfer area may yield more functional benefits.
Regarding the second point -the possibility that PEDF had a limited therapeutic effect on RP -this should be considered in more detail, since it is related to the choice of therapeutic gene. As demonstrated in Table 1 , PEDF treatment reproducibly resulted in a-wave4b-wave amplitude ratio. This result was fairly unusual, because the amplitude of b-wave, which corresponds to the mass response amplifying the signals from PCs, should be greater than that of a-wave. To explain this, we are now assessing the therapeutic effect of FGF-2, an alternative neurotrophic factor, on RCS rats via SIV-mediated gene transfer. Interestingly, although FGF-2 treatment resulted in a less pronounced effect in terms of both histology and a-wave amplitude than did PEDF treatment, b-waves in eyes treated with FGF-2 inversely demonstrated approximately two-fold higher amplitudes than those seen with PEDF (unpublished observation). Although it is still premature to reach a conclusion regarding these findings at present, a possible explanation might be that PEDF dominantly rescues PCs, but not secondary neurons. This hypothesis would be supported by the following findings: (1) neurotrophic factor-mediated activation, including FGF-2 but not PEDF, of intracellular signaling pathways has been observed in Muller cells and other cells of the inner retina, but not in PCs, 43 and (2) a possible PEDF receptor is located in the inner segment of PCs and the ganglion cell layer, but not in the inner nuclear layer. 44 In addition, the occurrence of an ERG pattern in which the a-waves have a greater amplitude than the b-waves is not unheard of, since such an unusual ERG ratio has been observed both in BALB/ cByJ nob/nob mice and in patients with complete Xlinked congenital stationary night blindness type 1. 45 According to our current data, PEDF holds the potential to provide retinal protection; however, we do not know whether this therapeutic gene will be sufficient to treat RP in human subjects. Our current study is, to the best of our knowledge, the first demonstration of a significant therapeutic effect of gene transfer in the use of PEDF, and we believe that PEDF is likely to be one of the better genes among the various neurotrophic factors because of its antiangiogenic ability through the induction of endothelial apoptosis. [34] [35] [36] Since the unexpected proliferation of neovessels is likely to worsen the patient's vision, PEDF would seem to be a good candidate for retinal gene therapy. Therefore, further studies will be needed to assist in the choice of appropriate therapeutic gene(s), and theoretically, the combination of PEDF and FGF-2 may be an option for more effective gene therapy.
Finally, while discussions regarding the relevancy of the delay of disease progression sufficient to matter to patients should be ongoing, we consider that it may be reasonable, because majority of RP diseases in human subjects progress over several decades. This clinical feature of RP suggests that a doubling of the disease time course by gene therapy may, at least in theory, be sufficient to allow patients with RP to retain their vision. Further evaluation of the utility of delaying the disease progression is needed, especially through clinical studies. A3  A4  A5  A6  A7  A8  A9  A10   A1  Wild  A2  A3  A4  A5  A6  A7  A8  A9  A10   A1  Wild  A2  A3  A4  A5  A6  A7  A8  A9 Figure 3 The mean number of photoreceptor nuclei per 100 mm retina along the horizontal meridian of the eye from the optic nerve head to the ora serrata of RCS rats at 4 weeks (a), 8 weeks (b), 12 weeks (c), and 24 weeks (d) after injection. The nearer the region was to the SIV-PEDF injection site, the better preserved were the photoreceptor nuclei.
In summary, we demonstrated that SIV-based lentivirus vector-mediated PEDF gene transfer to the retina of RCS rats could significantly protect against retinal degeneration, morphologically and functionally, and that this effect occurred, at least in part, via the inhibition of photoreceptor cell apoptosis. These findings suggest that SIV-based lentivirus vector-mediated PEDF gene transfer to the retina is a useful approach for RP.
Materials and methods
SIV vectors
Recombinant SIVs were constructed as previously described 21 . The SIVs encoding the E.coli lacZ gene, with simian virus 40 large T antigen nuclear localizing signal (SIV-nls-lacZ) and pigment epithelium-derived factor (SIV-PEDF), were propagated. A U3 region in the 3' and 5' long terminal repeat (3 0 and 5 0 LTR) of the SIV was deleted for self-inactivation, and the SIV vectors were pseudotyped with vesicular stomatitis virus envelope glycoprotein G (VSV-G). The virus titer was determined by transduction of the human embryonic kidney 293T cell line, and these viruses were kept at À801C until just before use.
Animals
The 3-week-old inbred RCS rats, which are pink-eyed, tan-hooded rats (gift of Professor Tamai, Tohoku University, Sendai, Japan), and congenic RCS-rdy rats of the wildtype at the rdy locus were maintained humanely, with proper institutional approval, and in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. All animal experiments were carried out under approved protocols and in 
Gene transfer procedures
The subretinal injection of each solution was performed as previously described with minor modifications. 21 Briefly, rats were anesthetized by inhalation ehtel. The following procedures were then performed using an operating microscope. A 30-gauge needle was inserted into the anterior chamber at the peripheral cornea, and anterior chamber fluid was drained off. A 30-gauge needle was inserted into the subretinal space of the peripheral retina in the nasal hemisphere via an external transscleral transchoroidal approach. The vector solution (10ml)(SIV-PEDF or SIV-nls-lacZ) (2.5 Â 10 7 transducing units (TU)/ml) or BSS: (137 mM NaCl, 5.4 mM KCl, 0.44 mM KH 2 PO 4 , 0.34 mM Na 2 HPO 4 , and 13 mM Tris, pH 7.6) was injected, and excess solution from the injection site was washed out using phosphate-buffered saline (PBS: 137 mM NaCl, 3 mM KCl, 8 mM Na 2 HPO 4 , and 1 mM KH 2 PO 4 , pH 7.2). Approximately 2-3 ml of solution remained in the subretinal space (data not shown). The appearance of a dome-shaped retinal detachment confirmed the subretinal delivery. Eyes that sustained prominent surgical trauma, such as retinal or subretinal hemorrhage or bacterial infection, were excluded from this examination.
X-gal histochemistry
The rats were killed, and the eyes were enucleated and fixed with ice-cooled 2% paraformaldehyde with 0.25% glutaraldehyde in 0.1 M PBS for 10 min. Then the eyes were washed with 0.1 M PBS containing 0.1% Triton-X followed by X-gal staining (solution: 5 mM potassium ferrous cyanide, 5 mM ferric cyanide, 2 mM magnesium chloride, 1 mg/ml 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside) for 3 h at room temperature. The X-galstained tissue was refixed and mounted in paraffin, and 5 mm-thick sections counterstained with nuclear fast red were examined under a light microscope.
Immunohistochemistry
The eyes of animals injected with SIV-PEDF, SIV-nls-lacZ, and BSS were enucleated at 4, 8, 12, and 24 weeks after injection. Eyecups were fixed with ice-cooled 4% paraformaldehyde in PBS for 1 day at room temperature. The eyes were mounted in paraffin, and 5 mm-thick sections were made and allowed to dry overnight. The sections were incubated for 1 h at room temperature using a monoclonal antibody to PEDF (CHEMICON International, Temecula, CA, USA) diluted in 1% bovine serum albumin (1/250). DACO catalyzed signal amplification (CSA) System peroxydase (DAKO, Carpinteria, CA, USA) was then used to amplify the signal of PEDF. Bound antibodies were detected by color modification of DAB by CoCl 2 to distinguish the signal from the melanin pigments. 46 After being washed with water, slides were counterstained with methyl green.
TUNEL staining
The rats were killed, and their eyes were enucleated and fixed with 4% paraformaldehyde in PBS. The eyes were mounted in paraffin in 5 mm-thick sections. To detect apoptotic cells, retinal sections were processed for TUNEL, using the ApopTag Fluorescein Direct In Situ Apoptosis Detection Kit (Intergen, Purchase, NY, USA) according to the recommendations of the manufacturer. After labeling, propidium iodide was used to counterstain the nuclei.
Electroretinograms
To exclude interanimal variation in the ERG recordings, in the case of SIV-PEDF injection to one eye, the opposite eye was usually treated with SIVnls-lacZ or BSS, or was not treated, as an internal control (4 weeks after injection: PEDF versus lacZ¼four animals, PEDF versus BSS¼three animals, PEDF versus untreated¼three animals, lacZ versus untreated¼ two animals, BSS versus untreated¼three animals; 8 weeks after injection: PEDF versus lacZ¼five animals, PEDF versus untreated¼three animals, lacZ versus BSS¼one animal). The data from some control animals are also included in Table 1 (where 'n' indicates the number of eyes). ERGs were recorded by a masked examiner (YG) without any information on whether the eyes were treated or untreated. Each animal was subjected to ERG study at several time points. The rats were kept in a dark room at least overnight before the experiment. The electroretinographic evaluations were performed using previously described methods. 47, 48 The rats were anesthetized with an intraperitoneal injection of 15 ml/g body weight of saline solution containing ketamine (1 mg/ml), myoblock (0.4 mg/ml), and urethane (40 mg/ml). Both pupils were dilated with 0.5% tropicamide and 0.5% phenylephrine hydrochloride, and the animals were placed on a heating pad. ERGs were recorded using a coiled stainless-steel wire containing the anesthetized (1% proparacaine HCl) corneal surface through a layer of 1% methylcellulose, and a similar wire was also placed in each of the leads. The responses were differentially amplified (band pass: 0.8-1200 Hz), averaged, and stored by a minicomputer (Signal Processor 7T17, NEC Sau-ei). Xenon strobe flash stimuli (to1 ms) were presented by a Ganzfeld stimulator (VPA-10; Cadwell, Kennewick, WA, USA) in the dark.
The dark-adapted ERGs were obtained using a flash intensity of 1.30 log cd-s/m 2 . The responses to five successive flashes in each rat were averaged. In addition, a 1-min interflash interval was used for this session. The ERG experiment was done in an identical manner 4 and 8 weeks after injection. PEDF-treated eyes always showed better ERG amplitudes than those seen in internal control eyes.
Statistical analyses
All values were expressed as the means7s.e.m. The data were analyzed by using a nonparametric test (MannWhitney U-test). A P-value of less than 0.05 was considered to be statistically significant.
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